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Introduction
============

Breast cancer constitutes one of the most important health problems in women, and survival depends on the size of the tumor and the involvement of lymph nodes at the time of diagnosis. Imaging of the breast tissue aims to screen asymptomatic cases and to evaluate the symptomatic patients properly. Since early diagnosis is the most crucial prognostic parameter, screening modalities have gained significance \[[@REF1]\].

Even though the primary screening modality is mammography (MG), the accuracy of this method is reduced remarkably in dense breast tissues in the pre-menopausal period and cases receiving hormone replacement treatment. Moreover, MG may fail to distinguish benign tumors from malignant lesions attributed to its low specificity \[[@REF2]-[@REF3]\].

Ultrasonography (USG) constitutes an alternative diagnostic tool, particularly for patients with obscure imaging features under MG. The conjunctive use of MG and USG may not be sufficient to identify and document the behavioral patterns, multicentricity, and planning of conservative surgery and distinguish a residual lesion from granulation tissue. In such circumstances, magnetic resonance imaging (MRI) can be a useful diagnostic measure \[[@REF4]-[@REF5]\]. Owing to the use of contrast agents, MRI became a highly sensitive imaging modality for the screening and diagnosis of breast tumors. The sensitivity and specificity of MRI were reported as 83%-99%, and 87%-97%, respectively \[[@REF6]-[@REF9]\].

The philosophy of MRI is based on the assessment of longitudinal relaxation time (T1), transverse relaxation time (T2), and hydrogen spin density of tissues under investigation. There has been controversy on whether a breast lesion with contrast enhancement on MRI should be evaluated with high spatial resolution or dynamic contrast views should be preferred to achieve higher sensitivity \[[@REF10]\]. Currently, attributed to the development of the MRI gradient system and pulse sequences, the concomitant use of high spatial resolution and sufficient temporal resolution has been popularized \[[@REF10]\].

Increased awareness and a better understanding of the pathologic features of breast tumors may be useful to interpret the MRIs. Large lesional size (\>10 mm), ill-defined margin, and irregular outline are mostly consistent with malignancy. These correlate with the pathological features of a breast tumor, characterized by the rapid growth rate, large size, infiltrative growth pattern, invasion into stroma resulting in desmoplasia, and, hence, irregular outline and margin. An integrated evaluation of clinical, radiological, and pathological characteristics is mandatory to accomplish highly accurate diagnostic outcomes \[[@REF11]\]. The morphology and enhancement kinetics are helpful for the recognition of malignant breast tumors. In addition to discrimination of malignant and benign lesions, MRI can provide advantages for the detection of axillary lymph node metastases and the identification of occult primary \[[@REF12]\].

The most commonly used reporting and classification system is Breast Imaging Reporting and Data System (BI-RADS®), which was used with high-resolution 3 T systems \[[@REF13]-[@REF14]\]. BI-RADS categorization has been employed for the breast lesions using the morphological features and time-signal contrast curves of the lump. Dynamic MRI is useful for the BI-RADS classification of the breast lesions and to foresee the histopathological diagnosis. Dynamic contrast-enhanced MRI constitutes an improved imaging modality with advanced accuracy for differentiation between benign and malignant lesions. Early enhancement is supposed to imply malignancy \[[@REF15]-[@REF16]\].

The present study aimed to evaluate the role of MRI in the visualization of breast lesions and to estimate whether MRI can be a reliable alternative to MG and USG for this purpose.

Materials and methods
=====================

Study design

This retrospective, single-center study was carried out in the radiology department of a tertiary care center between January 2014 and July 2019. The approval of the local institutional review board was obtained before the study (date: 01/2020 - no:530). The study was conducted in compliance with the principles of the Helsinki Declaration.

The descriptive and radiologic information was extracted from the medical files of our hospital database. Patients with breast lesions who were classified as BI-RADS 4 and 5 on MRI views were included. The consistency of the pathological lesions with the lesion type, contrast enhancement patterns, and radiological features on MRI was investigated. The harmony between BI-RADS classification and pathological diagnosis, as well as the accuracy for the demonstration of the axillary metastasis using MRI, were assessed. Patients who underwent both MG+USG and MRI for breast lesions were included in this study. All MRI views were evaluated by the same radiologist.

Data were collected from the medical records of 260 patients (258 women, 2 men) with an average age of 50.88±11.61 (range: 20 to 80).

Outcome measures

Baseline descriptions, such as age and gender, BI-RADS classifications as for MG+USG and MRI, features of the breast lump, such as the side, location, multi foci or multicentricity, histopathological diagnosis, contrast-enhancement characteristics, and radiological and pathological axillary involvement, were noted. The location of the lesion was classified as the upper outer quadrant, upper inner quadrant, lower outer quadrant, lower inner quadrant, and central. The side of the lesion was classified as right, left, or bilateral.

Conventional diagnostic imaging

All patients underwent digital MG (IMS Giotto, Italy) and targeted ultrasonographic examination of the affected breast and the ipsilateral axillary region. Ezu-MT28-S1 model (Hitachi Inc. Japan) and a 13 MHz linear transducer were used to evaluate the breast lesions before MRI. These examinations were performed by our radiology department in our tertiary care center.

MRI protocol

Magnetic resonance imaging examinations were carried out using a 1.5-T imaging uni (Signa, GE Healthcare, Chicago, Illinois). For the Signa scanner, the imaging parameters were as follows: 4.6/2.2; ﬂip angle, 10°; a field of view (FOV), 34 × 34 cm; matrix, 320 × 320; section thickness, 2 mm; and acquisition time, 75 seconds. Non-contrast T2 and T1-weighted images were obtained in the prone position using the breast coil. A 0.01 mmol/kg contrast agent was used for contrast imaging (gadoterate meglumine Dotarem®️, Guerbet; gadobutrol: Gadovist®️, Bayer Healthcare) at a rate of 2 mL/s, which was followed by a 20 mL saline flush at the rate of 2 mL/s). Dynamic contrast-enhanced images were obtained at minutes one, two, and six after contrast material injection. Post-processing manipulation included the production of standard subtraction and maximum-intensity-projection images (MIP). The images were transferred to a workstation (Advantage Windows, software version 4.0, GE Healthcare) for analysis.

Results
=======

The descriptive features of our series are presented in Table [1](#TAB1){ref-type="table"}. Our patient population (n=260) comprised 258 women and two men. The average age was 50.88±11.61 (range: 20 to 80). On MRI views, 92 lesions (35.4%) were reported as suspicious while 168 lumps were identified as highly probably malignant. The lesions most commonly involved the left side (n=132, 50.8%), followed by right side (n=113, 43.5%) and bilateral involvement (n=15, 5.8%). The number of multifocal and multicentric lesions were 40 (15.4%) and 35 (13.5%), respectively.

###### Descriptive data (n=260)

MRI - magnetic resonance imaging; MG - mammography; USG - ultrasonography

BI-RADS®: Breast Imaging Reporting and Data System

  ------------------------------------------------ --------------------------------------- ------ ------
                                                   n                                       \%     
  Sex                                              Male                                    2      0.8
  Female                                           258                                     99.2   
  MRI                                              Suspicious                              92     35.4
  Highly probably malignant                        168                                     64.6   
  Site of lesion                                   Right                                   113    43.5
  Left                                             132                                     50.8   
  Bilateral                                        15                                      5.8    
  Location of lesion                               Upper outer                             108    41.5
  Upper inner                                      39                                      15.0   
  Lower outer                                      43                                      16.5   
  Lower inner                                      20                                      7.7    
  Central                                          50                                      19.2   
  Multi foci                                       Yes                                     40     15.4
  No                                               220                                     84.6   
  Multicentricity                                  Yes                                     35     13.5
  No                                               225                                     86.5   
  BI-RADS for MG+USG/MRI                           Additional investigation needed         71     27.3
  Negative                                         3                                       1.2    
  Benign                                           10                                      3.8    
  Probably benign                                  15                                      5.8    
  Suspicious                                       47                                      18.1   
  Highly probably malignant                        78                                      30.0   
  Proven malignancy                                36                                      13.8   
  Histopathology                                   Benign                                  42     16.2
  Premalignant                                     207                                     79.6   
  Malignant                                        11                                      4.2    
  Lesion type                                      Mass lesion with contrast enhancement   193    74.2
  Contrast enhancement without mass lesion         62                                      23.8   
  Focus                                            5                                       2      
  Axillary involvement on MRI                      Yes                                     126    48.5
  No                                               134                                     51.5   
  Pathological axillary involvement                Yes                                     85     32.7
  No                                               121                                     46.5   
  Undetermined due to lack of surgical procedure   54                                      20.8   
  ------------------------------------------------ --------------------------------------- ------ ------

The assessment of breast MRI was performed by the same radiologist and the report included the indication for scan and clinical information in addition to the dose and type of contrast material administered to the patient. The image findings under foci were breast density, the amount of parenchymal background enhancement, and relevant findings such as axillary involvement and side and location of the lesion. Even though lymph node evaluation is not a particular aim of breast MRI, it can reveal unsuspected axillary nodal involvement. Each report was associated with a diagnostic category and recommendations. The most commonly used reporting and classification system is BI-RADS \[[@REF13]-[@REF14]\].

This system that provides the convenience of communication between clinic-radiology, as well as standardization of the studies, was offered by the American College of Radiology (ACR) in 1993 for the standardization of MG reporting terminology in the name BI-RADS \[[@REF17]\]. This internationally accepted system was reviewed in 2003 with the addition of the MG+USG and MRI classification \[[@REF18]\]. The BI-RADS diagnostic categories are demonstrated in Table [2](#TAB2){ref-type="table"}.

###### BI-RADS diagnostic categories

BI-RADS®: Breast Imaging Reporting and Data System

  ---------- -----------------------------------------------------
  Category   Definition
  0          Incomplete, additional imaging evaluation is needed
  1          Negative, no abnormalities
  2          Benign findings
  3          Probably benign findings
  4          Suspected malignancy
  5          Highly suspected malignancy
  6          Already histologically proven cancer
  ---------- -----------------------------------------------------

Figures [1](#FIG1){ref-type="fig"}-[2](#FIG2){ref-type="fig"} demonstrate two benign sclerosing adenoma lesions, which were false-positively diagnosed as BI-RADS 5 at MRI. Thus, it must be remembered that despite its high sensitivity and acceptable specificity, a substantial rate of false positive and false negative results are likely particularly if MRI is used alone.

![Benign sclerosing adenoma lesion\
Nonmass enhancement in the upper outer quadrant in the left breast was detected on maximum intensity projection (a), on the subtracted image (b), and on the first passage of dynamic enhancement images (c). The lesion was consistent with sclerosing adenosis.](cureus-0012-00000008087-i01){#FIG1}

![Benign sclerosing adenoma lesion\
A structural distortion area was detected in the lower outer quadrant of the left breast on the second (a) and sixth passages of dynamic enhancement images (b). The lesion was sclerosing adenosis.](cureus-0012-00000008087-i02){#FIG2}

In Table [3](#TAB3){ref-type="table"}, the agreement between the BI-RADS classification as for MRI and MG+USG and the relationship between the MRI BI-RADS category and other parameters under investigation were sought. The agreement ratio between the BI-RADS categories of MRI and MG+USG was 0.654 while consistency between histopathological diagnosis and MRI BI-RADS category was 0.838. The agreement between the BI-RADS category of MG+USG and histopathological diagnosis was 0.819.

###### Agreement ratios between MRI BI-RADS, MG + USG BI-RADS, axillary lymph node involvement on MRI and histopathological diagnosis

MRI: magnetic resonance imaging; MG: mammography, USG: ultrasonography; BI-RADS®: Breast Imaging Reporting and Data System

  ------------------------------------------------------------------- ----------- -------------- ------- -----------------
  Variables                                                           Agreement   Disagreement   Total   Agreement ratio
  MRI BI-RADS-MG+USG BIRADS                                           170         90             260     0.654
  MRI BI-RADS-Histopathological diagnosis                             218         42             260     0.838
  MG+USG BI-RADS-Histopathological diagnosis                          213         47             260     0.819
  MRI axillary lymph node-Histopathological diagnosis (specificity)   180         80             260     0.692
  MRI axillary lymph node-Histopathological diagnosis (sensitivity)   176         84             260     0.677
  ------------------------------------------------------------------- ----------- -------------- ------- -----------------

Table [4](#TAB4){ref-type="table"} outlines the agreement ratios between MRI BI-RADS, MG+USG BI-RADS, and histopathological diagnosis as for various radiological characteristics on dynamic MRI views. We observed that the consistency between MRI BI-RADS and MG+USG BI-RADS increased remarkably with the advancement of age. Similarly, the consistency between MRI BI-RADS and histopathological diagnosis tends to increase with the advancement of age. Nonmass enhancement yielded the highest agreement ratios between MRI BI-RADS and MG+USG BI-RADS, histopathological diagnosis and MRI BI-RADS, and histopathological diagnosis and MG+USG BI-RADS.

###### The agreement ratios between MRI BI-RADS, MG+USG BI-RADS and histopathological diagnosis as for various radiological characteristics on dynamic MRI views

MRI: magnetic resonance imaging; MG: mammography; USG: ultrasonography; BI-RADS®: Breast Imaging Reporting and Data System

  ---------------------------------------------- ----------- -------------- ------- -----------------
  MRI BI-RADS & MG+USG BI-RADS                   Agreement   Disagreement   Total   Agreement ratio
  Age groups                                                                        
  0-20                                           1           0              1       1.000
  21-40                                          33          9              42      0.786
  41-60                                          106         58             164     0.646
  \>60                                           30          23             53      0.566
  MRI BI-RADS & Histopathological Diagnosis                                         
  Age groups                                                                        
  0-20                                           1           0              1       1.000
  21-40                                          39          3              42      0.923
  41-60                                          139         25             164     0.820
  \>60                                           39          14             53      0.641
  MG+USG BI-RADS & Histopathological diagnosis                                      
  Age groups                                                                        
  0-20                                           1           0              1       1.000
  21-40                                          34          8              42      0.810
  41-60                                          135         29             164     0.823
  \>60                                           44          9              53      0.830
  MRI BI-RADS & MG+USG BI-RADS                                                      
  Side                                                                              
  Right                                          35          7              113     0.690
  Left                                           84          48             132     0.636
  Bilateral                                      8           7              15      0.533
  MRI BI-RADS & Histopathological diagnosis                                          
  Side                                                                              
  Right                                          93          20             113     0.823
  Left                                           110         22             132     0.833
  Bilateral                                      15          0              15      1.000
  MG+USG BI-RADS & Histopathological diagnosis                                       
  Side                                                                               
  Right                                          92          21             113     0.814
  Left                                           110         22             132     0.833
  Bilateral                                      11          4              15      0.733
  MRI BI-RADS & MG+USG BIRADS                                                       
  Location of neoplasm                                                              
  Upper outer quadrant                           70          38             108     0.648
  Upper inner quadrant                           24          15             39      0.615
  Lower outer quadrant                           34          9              43      0.791
  Lower inner quadrant                           11          9              20      0.550
  Central                                        31          19             50      0.620
  MRI BI-RADS & Histopathological diagnosis                                         
  Location of neoplasm                                                              
  Upper outer quadrant                           91          17             108     0.843
  Upper inner quadrant                           29          10             39      0.744
  Lower outer quadrant                           37          6              43      0.860
  Lower inner quadrant                           18          2              20      0.900
  Central                                        43          7              50      0.860
  MG+USG BI-RADS & Histopathological diagnosis                                      
  Location of neoplasm                                                              
  Upper outer quadrant                           91          17             108     0.843
  Upper inner quadrant                           32          7              39      0.821
  Lower outer quadrant                           33          10             43      0.767
  Lower inner quadrant                           15          5              20      0.750
  Central                                        42          8              50      0.840
  MRI BI-RADS & MG+USG BI-RADS                                                      
  Multifocal                                                                        
  No                                             144         76             220     0.655
  Yes                                            26          14             40      0.650
  MRI BI-RADS & Histopathological diagnosis                                         
  Multifocal                                                                        
  No                                             182         38             220     0.827
  Yes                                            36          4              40      0.900
  MG+USG BI-RADS & Histopathological diagnosis                                      
  Multifocal                                                                        
  No                                             181         39             220     0.823
  Yes                                            32          8              40      0.800
  MRI BI-RADS & MG+USG BI-RADS                                                      
  Multicentricity                                                                   
  No                                             145         80             225     0.644
  Yes                                            25          10             35      0.714
  MRI BI-RADS & Histopathological diagnosis                                          
  Multicentricity                                                                   
  No                                             188         37             225     0.836
  Yes                                            30          5              35      0.857
  MG+USG BI-RADS & Histopathological diagnosis                                      
  Multicentricity                                                                   
  No                                             184         41             225     0.818
  Yes                                            29          6              35      0.829
  MRI BI-RADS & MG+USG BI-RADS                                                      
  Type of lesion                                                                    
  Contrast enhanced mass                         122         71             193     0.632
  Contrast enhancement without mass              46          16             62      0.742
  Focal                                          1           1              2       0.500
  MRI BI-RADS &Histopathological diagnosis                                          
  Type of lesion                                                                    
  Contrast enhanced mass                         168         25             193     0.870
  Contrast enhancement without mass              45          17             62      0.726
  Focal                                          2           0              2       1.000
  MG+USG BI-RADS &Histopathological diagnosis                                        
  Type of lesion                                                                     
  Contrast enhanced mass                         162         31             193     0.839
  Contrast enhancement without mass              46          16             62      0.742
  Focal                                          2           0              2       1.000
  MRI BI-RADS & MG+USG BI-RADS                                                      
  Contrast enhancement                                                              
  Fast                                           89          41             130     0.685
  Slow                                           81          49             130     0.623
  MRI BI-RADS &Histopathological diagnosis                                          
  Contrast enhancement                                                              
  Fast                                           108         22             130     0.831
  Slow                                           110         20             130     0.846
  MG+USG BI-RADS &Histopathological diagnosis                                       
  Contrast enhancement                                                              
  Fast                                           112         18             130     0.862
  Slow                                           101         29             130     0.777
  ---------------------------------------------- ----------- -------------- ------- -----------------

Discussion
==========

We aimed to investigate the role of MRI in imaging breast lesions and in seeking the impacts of descriptive, clinical, and radiological variables on the agreement between MRI, MG+USG, and histopathological diagnosis. Our results demonstrated that the age of the patients, the location of the lesion, and enhancement characteristics might influence the ratio of agreement between MRI and MG+USG for the detection of breast neoplasms. Therefore, complementary use of imaging modalities together with an integrative analysis of clinical, pathological, and radiological data is mandatory to improve early and accurate diagnosis rates.

Magnetic resonance imaging is an important diagnostic measure in breast imaging, and dynamic contrast-enhanced MRI is the backbone of any breast MRI protocol, with excellent sensitivity and good specificity for breast cancer diagnosis. It yields high-resolution morphological information and functional data about angioneogenesis as a tumor-specific feature \[[@REF19]\].

The superiority of MRI is linked with its high sensitivity in tumor detection owing to the consistent contrast enhancement of breast cancer. In breast cancer, the enhancement of the tumor is always stronger than the normal breast tissue. Lack of enhancement reminds a benign lesion or normal tissue. Even pre-invasive lesions, such as lobular carcinoma in situ, showed stronger enhancement than normal glandular tissues. Malignant tumors of the breast frequently display an increased capillary network and increased permeability, and these factors contribute to the earlier and stronger contrast enhancement in breast malignancies \[[@REF19]\]. Even though MRI has an important role in the detection of breast cancers, primarily in high-risk patients, one should be aware of the fact that false-negative MR findings do occur in a small percentage of cases. MG remains the main diagnostic technique for examination of the breasts. The MR imaging technique is of complementary value in better delineation of tumor size, in recognition of additional malignant lesions, and in mammographically difficult, dense breasts \[[@REF20]\].

Reported high sensitivity (83%-100%) of MRI for breast cancer reinforced the presumption that non-enhancing lesions on MRI were benign and did not necessitate biopsy. However, it is known that not all malignant lesions display obvious contrast enhancement and enhancement was absent in up to 12% of malignant tumors \[[@REF21]\].

The reasons for the misdiagnosis of these lesions were technical challenges, reader perception problems secondary to masking by intensely enhancing parenchyma, small lesion size, and diffuse growth patterns. However, estimation of the types of malignant lesions that are more likely to be missed at MRI needs to be investigated in further trials.

Small tumor size and diffuse parenchymal enhancement were likely the principal reasons for these false-negative results. Although the overall sensitivity of breast MRI for cancer detection was high (96.8%), it should be emphasized that a negative MRI should not inﬂuence the management of a lesion that appears to be of concern on physical examination, mammography, or ultrasound. MRI is complementary to, but is not a replacement for, other breast imaging techniques and should not be used as the sole imaging study because, as this study shows, a small number of cancers may not be visible at MRI \[[@REF21]\].

The detection and characterization of malignant lesions are best performed using mammography and MRI. We suggest that making an MRI evaluation before proceeding to a histopathological diagnosis for suspected and indefinite breast lesions is the most preferable approach.

Our study possesses certain limitations such as retrospective design, selection bias, and lack of a control group. The possible impacts of biomechanical, social, environmental, and ethnic confounding factors must be remembered during the extrapolation of our results to larger populations.

Ideally, the radiologists dealing with breast imaging must be familiar and experienced with not only MRI but also they must be trained especially for conventional methods such as mammography and ultrasound. These methods are complementary to each other, rather than being alternatives. It must be remembered that integrative and multi-dimensional analysis of clinical, radiological, and pathological data is mandatory to reach the accurate diagnosis soon and to initiate the appropriate treatment without delay. Rather than using MRI instead of MG+USG or biopsy, MRI findings must be comparatively evaluated with other clinical and imaging findings.

Conclusions
===========

Breast MRI is a sensitive imaging modality that remarkably improves screening in high-risk women. It has important functions in clinical diagnosis and staging, affecting patient management. Nevertheless, it is not a fully perfect diagnostic tool since some breast tumors may be missed and some benign lesions may be misdiagnosed as malignant. Therefore, clinical and other imaging findings from other modalities, such as mammography and USG, must be reviewed. These drawbacks must be known and shared with the patient before the performance of a breast MRI. In conclusion, dynamic MRI is a useful and reliable method for imaging breast neoplasms.
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